Global liver cancer therapeutics market is forecast to grow in the coming years and reach $ 11 billion by 2025. Major factors behind the growth of this market include rising cases of liver cancer, globally, increasing alcohol consumption, aging population, and growing funding by both public and private sector in research and development activities for cancer cure. Liver cancer is a chronic and life-threatening disease which begins in cells of liver. Most of the liver cancer patients do not show the symptoms at early stages but in later stages, the common symptoms include loss of appetite, upper abdominal pain, nausea and vomiting and yellow discoloration of skin. According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe. Another major reason for the increase in the liver cancer is the high increase in the incidence of HBV/HCV coinfection and cirrhosis. Therefore, scientists are working on developing more innovative drugs and therapies for liver cancer treatment. However, the market also faces some restrains. Expensive treatments as well as high cost in research and development might hamper further development of liver cancer therapeutics market.

The global liver cancer therapeutics market is segmented based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region. Based on route of administration, the market is segmented into oral, intravenous and others. The oral segment is anticipated to dominate the global liver cancer therapeutics market during the forecast period as it is most preferred route of administration for chemotherapy. Based on distribution channel the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies are anticipated to dominate the market during the forecast period as the drugs are mostly purchased from the hospitals at the time of treatment. Based on therapy the market is segmented into chemotherapy and radiation therapy, immunotherapy, targeted therapy, and others. The chemotherapy and radiation therapy segment is anticipated to dominate the market through 2025.

The onset of COVID-19 has adversely impacted the market on account of significantly lower patient footfall in private clinics and hospital OPDs. Major players operating in the global liver cancer therapeutics market include Bayer AG, Alnylam Pharmaceuticals Inc., F. Hoffmann-La Roche AG , Bristol-Myers Squibb Company, Eisai Co., Ltd. , Pfizer Inc., Exelixis, Inc., Merck, Celsion Corporation, Johnson & Johnson, Novartis International AG, Sanofi S.A., Eli Lilly and Company, Perkin Elmer, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Amgen Inc., AstraZeneca, Philips Healthcare Pvt. Ltd and others.

Years considered for this report:

  • Historical Years: 2015-2018
  • Base Year: 2019
  • Estimated Year: 2020
  • Forecast Period: 2021–2025

Objective of the Study:

  • To analyze and forecast the market size of global liver cancer therapeutics market.
  • To classify and forecast global liver cancer therapeutics market based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region.
  • To identify drivers and challenges for global liver cancer therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global liver cancer therapeutics market.
  • To conduct pricing analysis for global liver cancer therapeutics market.
  • To identify and analyze the profile of leading players operating in global liver cancer therapeutics market.


TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of leading players operating across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include market players, which could not be identified due to the limitations of secondary research. TechSci Research analyzed the market players, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global liver cancer therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Liver cancer therapeutics players and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to liver cancer therapeutics
  • Market research and consulting firms


The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as market players, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:
In this report, global liver cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Cancer Type:


o Hepatocellular Carcinoma
o Cholangiocarcinoma
o Hepatoblastoma
o Angiosarcoma
o Liver Metastasis

  • Market, By Therapy:


o Targeted Therapy
o Chemotherapy and Radiation Therapy
o Immunotherapy
o Others

  • Market, By Equipment:


o Computed Radiography
o Sonography
o MRI
o Others

  • Market, By Age:


o 0-18
o 18-35
o 35-50


  • o 50+
  • Market, By Factors:


o Cirrhosis
o Nonalcoholic Fatty Liver Disease
o Excessive Alcohol Consumption
o Others

  • Market, By Route of Administration:


o Oral
o Intravenous
o Others

  • Market, By Distribution Channel:


o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies

  • Market, By Region:


o North America
 United States
 Canada
 Mexico
 Europe
 Germany
 France
 United Kingdom
 Italy
 Spain
 Asia-Pacific
 China
 Japan
 India
 South Korea
 Australia
 Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
 South America
 Brazil
 Argentina
 Colombia

Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global liver cancer therapeutics market.

Available Customizations:
The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).